[go: up one dir, main page]

MX2024001744A - Formulaciones de radiprodil. - Google Patents

Formulaciones de radiprodil.

Info

Publication number
MX2024001744A
MX2024001744A MX2024001744A MX2024001744A MX2024001744A MX 2024001744 A MX2024001744 A MX 2024001744A MX 2024001744 A MX2024001744 A MX 2024001744A MX 2024001744 A MX2024001744 A MX 2024001744A MX 2024001744 A MX2024001744 A MX 2024001744A
Authority
MX
Mexico
Prior art keywords
radiprodil
formulations
disorders
treatment
present disclosure
Prior art date
Application number
MX2024001744A
Other languages
English (en)
Inventor
Marie Genin
Pierandrea Muglia
Original Assignee
Grin Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Grin Therapeutics Inc filed Critical Grin Therapeutics Inc
Publication of MX2024001744A publication Critical patent/MX2024001744A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente descripción proporciona, en parte, composiciones farmacéuticas que comprenden radiprodil y excipientes farmacéuticamente aceptables y métodos de uso de las mismas en el tratamiento de trastornos tales como trastornos epilépticos.
MX2024001744A 2021-08-06 2022-08-05 Formulaciones de radiprodil. MX2024001744A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163230331P 2021-08-06 2021-08-06
PCT/US2022/039543 WO2023014956A1 (en) 2021-08-06 2022-08-05 Formulations of radiprodil

Publications (1)

Publication Number Publication Date
MX2024001744A true MX2024001744A (es) 2024-04-23

Family

ID=83189017

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024001744A MX2024001744A (es) 2021-08-06 2022-08-05 Formulaciones de radiprodil.

Country Status (12)

Country Link
US (1) US20250127770A1 (es)
EP (1) EP4380547A1 (es)
JP (1) JP2024529185A (es)
KR (1) KR20240052765A (es)
CN (1) CN118019521A (es)
AU (1) AU2022323381A1 (es)
CA (1) CA3228004A1 (es)
CO (1) CO2024002715A2 (es)
IL (1) IL310652A (es)
MX (1) MX2024001744A (es)
PE (1) PE20241385A1 (es)
WO (1) WO2023014956A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025137652A2 (en) * 2023-12-20 2025-06-26 Grin Therapeutics, Inc. Methods of using radiprodil in the treatment of disorders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK287726B6 (en) 2001-07-24 2011-07-06 Richter Gedeon Vegyeszet Carboxylic acid amide derivatives, their preparation, pharmaceutical compositions containing them and process for preparing pharmaceutical compositions
EA201170007A1 (ru) * 2008-07-08 2011-08-30 Рихтер Гедеон Нирт. Новая кристаллическая форма 2-[4-(4-фторбензил)пиперидин-1-ил]-2-оксо-n-(2-оксо-2,3-дигидробензоксазол-6-ил)ацетамида
JP2012500801A (ja) * 2008-08-21 2012-01-12 リヒター ゲデオン ニルバーノシャン ミーケデーレスベニュタールシャシャーグ Ｃｎｓ疾患の治療法
HUP0900130A3 (en) 2009-03-03 2012-02-28 Richter Gedeon Nyrt Novel crystalline hydrate, amorphous and polymorphic forms of dihydro-benzoxazole-6-yl-acetamide derivative and processes for their preparation
US8328687B2 (en) 2010-07-09 2012-12-11 Ford Global Technologies, Llc Method for controlling an engine that may be automatically stopped

Also Published As

Publication number Publication date
JP2024529185A (ja) 2024-08-01
US20250127770A1 (en) 2025-04-24
EP4380547A1 (en) 2024-06-12
KR20240052765A (ko) 2024-04-23
WO2023014956A9 (en) 2023-12-14
CO2024002715A2 (es) 2024-05-20
PE20241385A1 (es) 2024-07-09
CN118019521A (zh) 2024-05-10
AU2022323381A1 (en) 2024-03-21
WO2023014956A1 (en) 2023-02-09
CA3228004A1 (en) 2023-02-09
IL310652A (en) 2024-04-01

Similar Documents

Publication Publication Date Title
CL2019000245A1 (es) Moduladores nmda espiro-lactam y métodos de uso de los mismos.
CL2019000248A1 (es) Moduladores del receptor nmda espiro-lactam y uso de los mismos
CO2018013747A2 (es) Moduladores del receptor espiro-lactama n-metil-d-aspartato y usos de los mismos
CO2019000941A2 (es) Moduladores del receptor nmda espiro-lactam y uso de los mismos
CO2019000943A2 (es) Moduladores del receptor nmda espiro-lactam y uso de los mismos
CO2019000944A2 (es) Moduladores del receptor nmda spiro-lactam y bis-spiro-lactam y uso de los mismos
EP4599848A3 (en) Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant
BR112015018094A2 (pt) moduladores de receptor nmda de espiro-lactama e usos dos mesmos
BR112015018087A2 (pt) moduladores de receptor nmda de espiro-lactama e usos dos mesmos
CO2023013050A2 (es) Composiciones de psilocibina, métodos para prepararlas y métodos de uso de estas
MX2018011102A (es) Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para uso en el tratamiento de tumores solidos.
BR112015018089A2 (pt) moduladores de receptor de nmda de espiro-lactama e usos dos mesmos
MX392572B (es) Compuestos del péptido yy (pyy) selectivos y sus usos.
CA3030422C (en) Stabilizing excipients for therapeutic protein formulations
PH12020500543A1 (en) Nonracemic mixtures and uses thereof
MX2021006012A (es) Derivados de amino triazolo quinazolina 7-, 8-, y 10-sustituidos como antagonistas de receptor de adenosina, composiciones farmaceuticas y su uso.
MX2021005839A (es) Antagonistas del receptor de adenosina aminotriazolopirimidina y aminotriazolopirazina sustituidos, composiciones farmaceuticas y su uso.
CO2024002715A2 (es) Formulaciones de radiprodil
CY1125075T1 (el) Εκχυλισμα salvia haenkei σαν δραστικος παραγοντας στις διαδικασιες επανεπιθηλιωσης και επουλωσης ιστων
AU2018260628A1 (en) Pharmaceutical composition comprising tryptophan and phyllokinin derivative for use in treating psychiatric and psychological conditions
CO2020012484A2 (es) Inhibidores de secreción de proteínas basados en triazaciclododecansulfonamida ("tcd")
AR114282A1 (es) Inhibidores de secreción de proteínas basados en triazaciclododecansulfonamida (“tcd”)
AR117386A1 (es) Composiciones farmacéuticas tópicas para la piel que contienen cerdulatinib y usos de las mismas
UA113771C2 (xx) Фармацевтична композиція у формі дерматологічної мазі для лікування алергічних і запальних захворювань шкіри